StockData
Climb Bio, Inc. logo

Climb Bio, Inc. (CLYM) stock

CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$9.78−0.16 (-1.61%)

Close on Nov 17, 2026Market cap $561.73MP/E –Yield –

Climb Bio r&d expenses

Research and development expenses are spending on new products and technology.

Climb Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $41.90M, up 16.1% year over year. For fiscal 2025 it was $46.71M, up 225.8% from the year before. The highest annual figure on record is $46.71M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$46.71M+225.8%
FY2024Dec 31, 2024$14.34M-7.0%
FY2023Dec 31, 2023$15.41M-41.2%
FY2022Dec 31, 2022$26.21M+12.4%
FY2021Dec 31, 2021$23.32M+166.0%
FY2020Dec 31, 2020$8.77M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.71M+47.7%
Q1 FY2026Mar 31, 2026$9.37M-45.9%
Q4 FY2025Dec 31, 2025$13.74M+130.5%
Q3 FY2025Sep 30, 2025$9.07M+45.4%
Q2 FY2025Jun 30, 2025$6.58M+528.6%
Q1 FY2025Mar 31, 2025$17.33M+1488.2%
Q4 FY2024Dec 31, 2024$5.96M+90.6%
Q3 FY2024Sep 30, 2024$6.24M+117.0%
Q2 FY2024Jun 30, 2024$1.05M-71.6%
Q1 FY2024Mar 31, 2024$1.09M-80.9%
Q4 FY2023Dec 31, 2023$3.13M-36.5%
Q3 FY2023Sep 30, 2023$2.88M-32.5%
Q2 FY2023Jun 30, 2023$3.69M-57.9%
Q1 FY2023Mar 31, 2023$5.72M-30.8%
Q4 FY2022Dec 31, 2022$4.93M-28.4%
Q3 FY2022Sep 30, 2022$4.26M-28.9%
Q2 FY2022Jun 30, 2022$8.77M+60.1%
Q1 FY2022Mar 31, 2022$8.26M+93.3%
Q4 FY2021Dec 31, 2021$6.88M+66.8%
Q3 FY2021Sep 30, 2021$5.99M+210.3%
Q2 FY2021Jun 30, 2021$5.48M+313.4%
Q1 FY2021Mar 31, 2021$4.27M–
Q4 FY2020Dec 31, 2020$4.13M–
Q3 FY2020Sep 30, 2020$1.93M–
Q2 FY2020Jun 30, 2020$1.33M–

More Climb Bio figures

See a number that looks wrong?